Drug Information

    


 












Pharmacokinetics

 

It directly
converts plasminogen to active plasma.

TOP

   

Indication
& Dosage


 

PULMONARY
EMBOLISM (PE), DEEP VEIN THROMBOSIS (DVT):


Initially 4400 IU/kg over 10
min followed by 4400 IU/kg/hr. Alternatively in PE, 15000 IU/kg may be
given as bolus injection into pulmonary artery repeated every 24 hrs for
3 doses.

Intra coronary ACUTE MI : 6000 IU/min for up to
2 hrs should be preceded
by IV heparin or IV doses of UK at 2-3 mio units over 45 to 90 min.




Catheter



PERIPHERAL VASCULAR OCCLUSION:
4000 UNITS/MIN via a catheter into the
clot as a solution containing 2500 unit/ml. Catheter is advanced into
the occlusion every 2 hrs until free flow is resumed.

CLEARANCE OF OCCLUDED CATHETERS AND SHUNTS: Up to 25000 units in 2-3 ml
of 0.9% Nacl instilled and clamped off for 2-4 hrs

TOP

   

Action

 



A thrombolytic agent obtained from human kidney cells by tissue culture.
Urokinase directly convert plasminogen into plasmin which then degrades
fibrin clots as well as fibrinogen and other plasma proteins.






TOP

   

Interactions

 


Aspirin, Cefamandole, Divalproex,
Enoxaparin, Heparin, Indomethacin, anti-inflammatory drugs or analgesics
(except narcotics), Phenylbutazone, Plicamycin, Sulfinpyrazone,
Ticlopidine or Valproic acid: when used together with Urokinase
increases the chances of bleeding .






TOP



   



Adverse
Effect & Precaution




Drug fever, haemorrhage

  

Allergies:
Allergic reaction to Urokinase may occur. Pregnancy :There is a slight
chance that use of a thrombolytic agent during the first five months of
pregnancy may cause a miscarriage. Older adults: The need for treatment
with a thrombolytic agent may be increased in elderly patients with
blood clots, however, the chance of bleeding may also be increased.

Pregnancy: Safety not established.

Breast Feeding: Safety not establishe.

Man: Use with caution.





TOP

    

Brand
available in market














DABUNASE

 

 

Dabur

INJ

250000i.u.

VIAL

1900.00

INJ

250000i.u.

VIAL

3600.00

KD-UNASE

 

 

VHB

VIAL

250000I.U

VIAL

2100.00

VIAL

500000I.U

VIAL

3200.00

UROKINASE

 

  

TTK

VIAL

50000iu

 

541.65

VIAL

250000iu

 

2080.00

VIAL

500000iu

 

3640.00

VIAL

750000iu

 

4861.11

VAIL

1000000IU

 

6527.78

 


TOP

  


       





 

 

  
Drug Information
    

 

Pharmacokinetics
 
It directly converts plasminogen to active plasma.

TOP
   

Indication & Dosage
 
PULMONARY EMBOLISM (PE), DEEP VEIN THROMBOSIS (DVT):

Initially 4400 IU/kg over 10 min followed by 4400 IU/kg/hr. Alternatively in PE, 15000 IU/kg may be given as bolus injection into pulmonary artery repeated every 24 hrs for 3 doses.
Intra coronary ACUTE MI : 6000 IU/min for up to 2 hrs should be preceded by IV heparin or IV doses of UK at 2-3 mio units over 45 to 90 min.

Catheter
PERIPHERAL VASCULAR OCCLUSION: 4000 UNITS/MIN via a catheter into the clot as a solution containing 2500 unit/ml. Catheter is advanced into the occlusion every 2 hrs until free flow is resumed.
CLEARANCE OF OCCLUDED CATHETERS AND SHUNTS: Up to 25000 units in 2-3 ml of 0.9% Nacl instilled and clamped off for 2-4 hrs

TOP
   

Action
 
A thrombolytic agent obtained from human kidney cells by tissue culture. Urokinase directly convert plasminogen into plasmin which then degrades fibrin clots as well as fibrinogen and other plasma proteins.


TOP
   

Interactions
 

Aspirin, Cefamandole, Divalproex, Enoxaparin, Heparin, Indomethacin, anti-inflammatory drugs or analgesics (except narcotics), Phenylbutazone, Plicamycin, Sulfinpyrazone, Ticlopidine or Valproic acid: when used together with Urokinase increases the chances of bleeding .


TOP
   

Adverse Effect & Precaution

Drug fever, haemorrhage
  
Allergies: Allergic reaction to Urokinase may occur. Pregnancy :There is a slight chance that use of a thrombolytic agent during the first five months of pregnancy may cause a miscarriage. Older adults: The need for treatment with a thrombolytic agent may be increased in elderly patients with blood clots, however, the chance of bleeding may also be increased.
Pregnancy: Safety not established.
Breast Feeding: Safety not establishe.
Man: Use with caution.


TOP
    

Brand available in market

DABUNASE

 

 

Dabur

INJ

250000i.u.

VIAL

1900.00

INJ

250000i.u.

VIAL

3600.00

KD-UNASE

 

 

VHB

VIAL

250000I.U

VIAL

2100.00

VIAL

500000I.U

VIAL

3200.00

UROKINASE

 

  

TTK

VIAL

50000iu

 

541.65

VIAL

250000iu

 

2080.00

VIAL

500000iu

 

3640.00

VIAL

750000iu

 

4861.11

VAIL

1000000IU

 

6527.78

 

TOP
  
       

 

By |2022-07-20T16:42:48+00:00July 20, 2022|Uncategorized|Comments Off on Urokinase

About the Author: